Literature DB >> 17907285

Chinese medicinal compound delisheng has satisfactory anti-tumor activity, and is associated with up-regulation of endostatin in human hepatocellular carcinoma cell line HepG2 in three-dimensional culture.

Jie Cui1, Ke-Jun Nan, Tao Tian, Ya-Huan Guo, Na Zhao, Lin Wang.   

Abstract

AIM: To investigate the multicellular resistance of human hepatocellular carcinoma HepG2 cells in three-dimensional culture to delisheng, 5-fluorouracil and adriamycin, and the possible molecular mechanisms of delisheng.
METHODS: Human hepatocellular carcinoma HepG2 cells were cultured with a liquid overlay technique. After the formation of multicellular spheroids, morphology was analyzed by phase contrast microscopy, scanning electron microscopy and transmission electron microscopy. Sensitivity of HepG2 cells to delisheng, 5-fluorouracil and adriamycin was investigated by MTT assay in multicelluar spheroids and monolayers. Vascular endothelial growth factor (VEGF) and endostatin expression were analyzed in multicellular spheroids treated with delisheng, 5-fluorouracil, adriamycin and negative control PBS, with immunohistochemical staining.
RESULTS: Multicellular spheroids exhibited structural characteristics somewhat different to those in monolayers. The cells in three-dimensional cell culture turned out to be less sensitive to delisheng, 5-fluorouracil and adriamycin than the cells cultured in monolayer. This showed that delisheng had a satisfactory cells inhibition ratio compared to 5-fluorouracil and adriamycin. Immunohistochemical staining showed that VEGF and endostatin expression was positive during growth as multicellular spheroids, and endostatin expression in spheroids with treatment of delisheng was higher than that with 5-fluorouracil, adriamycin and PBS (139.35 +/- 7.83, 159.23 +/- 10.34, 162.83 +/- 3.47 and 148.48 +/- 11.06, P < 0.05).
CONCLUSION: Chinese medicine compound delisheng has satisfactory anti-tumor activity in HepG2 cells in three-dimensional culture, and the effects are associated with up-regulation of endostatin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17907285      PMCID: PMC4171276          DOI: 10.3748/wjg.v13.i41.5432

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  Predicting aggregation kinetics of DU 145 prostate cancer cells in liquid-overlay culture.

Authors:  Kim C O'Connor; Mark Z Venczel
Journal:  Biotechnol Lett       Date:  2005-11       Impact factor: 2.461

2.  Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors.

Authors:  Malin Sund; Yuki Hamano; Hikaru Sugimoto; Akulapalli Sudhakar; Mary Soubasakos; Udaya Yerramalla; Laura E Benjamin; Jack Lawler; Mark Kieran; Amish Shah; Raghu Kalluri
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

Review 3.  Systemic therapy for hepatocellular carcinoma.

Authors:  T W Leung; P J Johnson
Journal:  Semin Oncol       Date:  2001-10       Impact factor: 4.929

4.  Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding.

Authors:  N Yamaguchi; B Anand-Apte; M Lee; T Sasaki; N Fukai; R Shapiro; I Que; C Lowik; R Timpl; B R Olsen
Journal:  EMBO J       Date:  1999-08-16       Impact factor: 11.598

5.  Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.

Authors:  M Jang; L Cai; G O Udeani; K V Slowing; C F Thomas; C W Beecher; H H Fong; N R Farnsworth; A D Kinghorn; R G Mehta; R C Moon; J M Pezzuto
Journal:  Science       Date:  1997-01-10       Impact factor: 47.728

Review 6.  Hepatocellular carcinoma.

Authors:  K Okuda
Journal:  J Hepatol       Date:  2000       Impact factor: 25.083

7.  Modulating angiogenesis: the yin and the yang in ginseng.

Authors:  Shiladitya Sengupta; Sue-Anne Toh; Lynda A Sellers; Jeremy N Skepper; Pieter Koolwijk; Hi Wun Leung; Hin-Wing Yeung; Ricky N S Wong; Ram Sasisekharan; Tai-Ping D Fan
Journal:  Circulation       Date:  2004-08-30       Impact factor: 29.690

Review 8.  The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.

Authors:  Josep M Llovet; Josep Fuster; Jordi Bruix
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

Review 9.  Liquid-overlay culture of cellular spheroids.

Authors:  J Carlsson; J M Yuhas
Journal:  Recent Results Cancer Res       Date:  1984

10.  Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma.

Authors:  M Mabed; L El-Helw; S Shamaa
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more
  7 in total

Review 1.  Traditional Chinese medicine for prevention and treatment of hepatocarcinoma: From bench to bedside.

Authors:  Bing Hu; Shuang-Shuang Wang; Qin Du
Journal:  World J Hepatol       Date:  2015-05-28

2.  A survey on herbal management of hepatocellular carcinoma.

Authors:  Nabil Mohie Abdel-Hamid; Maiiada Hasan Nazmy; Ahmed Wahid Mahmoud; Michael Atef Fawzy; Marco Youssof
Journal:  World J Hepatol       Date:  2011-07-27

3.  Cytotoxic activity of anticancer drugs on hepatocellular carcinoma cells in hypoxic-hyponutritional culture.

Authors:  Qiang Li; Lin-Zhong Zhu; Ren-Jie Yang; Xu Zhu
Journal:  Int Surg       Date:  2014 Nov-Dec

4.  Delisheng Injection (), a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3.

Authors:  Xi-lin Dong; Ying Gong; Zhen-zhen Chen; Ya-juan Wang
Journal:  Chin J Integr Med       Date:  2013-10-23       Impact factor: 1.978

5.  Antiproliferative Activity of the Chinese Medicinal Compound, Delisheng, Compared With Rg3 and Gemcitabine in HepG2 Cells.

Authors:  S H Wang; Y C Wang; Y L Nie; Y N Hai; H F Sun; Z L Yuan; K J Nan
Journal:  Indian J Pharm Sci       Date:  2013-09       Impact factor: 0.975

6.  Network Meta-Analysis of Chinese Herbal Injections Plus the FOLFOX Regimen for the Treatment of Colorectal Cancer in China.

Authors:  Dan Zhang; Jiarui Wu; Xiaojiao Duan; Kaihuan Wang; Mengwei Ni; Shuyu Liu; Xiaomeng Zhang; Bing Zhang; Yi Zhao
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

7.  β1 integrin-mediated multicellular resistance in hepatocellular carcinoma through activation of the FAK/Akt pathway.

Authors:  Tao Tian; Chun-Li Li; Xiao Fu; Shu-Hong Wang; Jun Lu; Hui Guo; Yu Yao; Ke-Jun Nan; Yu-Juan Yang
Journal:  J Int Med Res       Date:  2018-01-14       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.